Parr Mcknight Wealth Management Group LLC Buys Shares of 5,539 Bristol-Myers Squibb (NYSE:BMY)

Parr Mcknight Wealth Management Group LLC acquired a new stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 5,539 shares of the biopharmaceutical company's stock, valued at approximately $313,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Transce3nd LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Fairway Wealth LLC purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $28,000. Comprehensive Financial Planning Inc. PA purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $34,000. Tacita Capital Inc purchased a new position in Bristol-Myers Squibb in the fourth quarter valued at $39,000. Finally, M Holdings Securities Inc. acquired a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at about $39,000. Hedge funds and other institutional investors own 76.41% of the company's stock.

Bristol-Myers Squibb Stock Up 0.7%

Shares of Bristol-Myers Squibb stock traded up $0.31 during trading hours on Thursday, hitting $47.28. The company had a trading volume of 3,257,369 shares, compared to its average volume of 13,101,646. The company's 50-day moving average is $50.97 and its two-hundred day moving average is $55.54. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15. The company has a market cap of $96.23 billion, a P/E ratio of -10.70, a price-to-earnings-growth ratio of 2.07 and a beta of 0.39.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.50 by $0.30. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The company's revenue for the quarter was down 5.6% on a year-over-year basis. During the same quarter in the prior year, the business posted ($4.40) EPS. Analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were paid a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.24%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on BMY. UBS Group lowered their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 target price on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. Wells Fargo & Company upped their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a research note on Friday, February 7th. Jefferies Financial Group lowered their price target on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a report on Wednesday, April 23rd. Finally, Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a report on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the company. According to MarketBeat, Bristol-Myers Squibb presently has an average rating of "Hold" and an average target price of $58.00.

Insider Buying and Selling

In other news, EVP Samit Hirawat acquired 4,250 shares of the business's stock in a transaction on Friday, April 25th. The stock was bought at an average price of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 0.09% of the stock is owned by company insiders.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.